PolyU collaborates with Increasepharm (HK) Limited for CM-based new drug development

PolyU received generous support of HK $10 million from Increasepharm (HK) Limited to establish the PolyU – Increasepharm Joint Research Laboratory for New Drug Development (“The Joint Laboratory”). A signing ceremony was held on 15 June 2022 via hybrid mode.

During the ceremony, Prof. Zhang Baoxian, Chairman of Beijing Increasepharm Corporation Limited stated that The Joint Laboratory would capitalise on the opportunities brought by the country’s development, further extend the strategic partnership towards the Greater Bay Area (GBA) and conduct cutting-edge collaborative researches on developing nanomedicine and aerosolized medications for treating ocular diseases and osteoporosis.

The Joint Laboratory is under the PolyU Research Centre for Chinese Medicine Innovation (RCMI). Prof. Wong Man-sau, Director of RCMI, expressed her gratitude to Prof. Zhang and said, “The establishment of The Joint Laboratory would strengthen the current collaborative researches on osteoporosis drug development. On one hand, it would leverage the advantages of Increasepharm in synthetic chemistry and industrialisation of new drugs, making the pathway for the industrialisation of PolyU’s pharmaceutical research results. The Joint Laboratory would be committed to developing a series of herbal-based small-molecule drug, including innovative drugs for treatment of dementia and prevention of cognitive decline; On the other hand, it would explore and deliver innovative drugs for the treatment of ophthalmic diseases with the Novel Drug Delivery System. The Joint Laboratory would not only complement each other’s research strengths and technological capabilities but also provide a training base to all parties concerned.”